| Assay ID | Title | Year | Journal | Article |
|---|
| AID62755 | In vitro effective concentration tested on HEK293 cells co-transfected with human Dopamine receptor D2 using FLIPR assay; Not an agonist up to 10 uM | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID64024 | In vitro efficacy tested on human Dopamine receptor D4.4 were co-expressed with GRqo5 in HEK293 cells using FLIPR assay (Efficacy relative to 10 uM dopamine) | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID179649 | In vivo maximal effective dose tested in rats for erection 60 min after subcutaneous administration | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID274442 | Agonist activity at rat D4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID274448 | Agonist activity at rat D4 receptor in HEK293 cells co-expressing Galphaqo5 by FLIPR relative to dopamine | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID63828 | In vitro effective concentration tested on HEK293 cells co-transfected with rat Dopamine receptor D4 using FLIPR assay | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID3843 | In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID63215 | In vitro binding affinity tested on human Dopamine receptor D2 (short) using [3H]spiperone as a radioligand | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID61224 | In vitro effective concentration tested on HEK293 cells co-transfected with ferret Dopamine receptor D2 using FLIPR assay; Not an agonist up to 10 uM | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID169229 | In vivo maximal penile erection in rats 60 min after subcutaneous administration | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID65923 | D4 efficacy was measured using recombinant human Dopamine receptor D4 expressed in HEK293 cells | 2004 | Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
| Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning. |
| AID63528 | Binding affinity against human Dopamine receptor D4 by [3H]-spiperone displacement. | 2004 | Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
| Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning. |
| AID274455 | Activity at human D4.4 receptor in HEK293 cells co-expressing Galphaqo5 by FLIPR | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID64022 | In vitro EC50 tested on HEK293 cells co-transfected with human Dopamine receptor D4.4 using FLIPR assay | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID63703 | In vitro effective concentration tested on HEK293 cells co-transfected with ferret Dopamine receptor D4 using FLIPR assay | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID63213 | In vitro binding affinity tested on human Dopamine receptor D2 using [3H]spiperon as a radioligand | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID63831 | In vitro efficacy tested on rat Dopamine receptor D4 were co-expressed with GRqo5 in HEK293 cells using FLIPR assay (Efficacy relative to 10 uM dopamine) | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID274440 | Agonist activity at human D4.4 receptor in HEK293 cells co-expressing Galphaqo5 by FLIPR with relative to dopamine | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID65930 | D4 efficacy was measured using recombinant human D4 receptor expressed in HEK293 cells | 2004 | Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
| Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning. |
| AID61227 | In vitro effective concentration tested on HEK293 cells co-transfected with rat Dopamine receptor D2 using FLIPR assay; Not an agonist up to 10 uM | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID63214 | In vitro binding affinity tested on human Dopamine receptor D2 (long) using [3H]spiperon as a radioligand | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID63830 | In vitro efficacy tested on ferret Dopamine receptor D4 were co-expressed with GRqo5 in HEK293 cells using FLIPR assay (Efficacy relative to 10 uM dopamine) | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. |
| AID274437 | Agonist activity at human D4.4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |